First description of the complete human xylosyltransferase-I promoter region

BMC Genetics

Doris Hendig¹  Cornelius Knabbe¹  Joachim Kuhn¹  Christoph Lichtenberg¹  Kai Oliver Böker¹  Isabel Faust¹ 

[1] Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany

关键词: Gene regulation;    Microsatellite;    Single-nucleotide variant;    Promoter;    Xylosyltransferase;   

Others  :  1085171
DOI  :  10.1186/s12863-014-0129-0

 received in 2014-07-24, accepted in 2014-11-17,  发布年份 2014

【 摘 要 】

Background

Human xylosyltransferase-I (XT-I) catalyzes the rate-limiting step in proteoglycan glycosylation. An increase in XYLT1 mRNA expression and serum XT activity is associated with diseases characterized by abnormal extracellular matrix accumulation like, for instance, fibrosis. Nevertheless, physiological and pathological mechanisms of transcriptional XT regulation remain elusive.

Results

To elucidate whether promoter variations might affect the naturally occurring variability in serum XT activity, a complete sequence analysis of the XYLT1 promoter was performed in genomic DNA of healthy blood donors. Based on promoter amplification by a specialized PCR technique, sequence analysis revealed a fragment of 238 bp, termed XYLT1_238*, which has never been described in the human XYLT1 reference sequence so far. In silico characterization of this unconsidered fragment depicted an evolutionary conservation between sequences of Homo sapiens and Pan troglodytes (chimpanzee) or Mus musculus (mouse), respectively. Promoter activity studies indicated that XYLT1_238* harbors various transcription factor binding sites affecting basal XYLT1 expression and inducibility by transforming growth factor-β1, the key fibrotic mediator.

A microsatellite and two single nucleotide variants (SNV), c.-403C>T and c.-1088C>A, were identified and genotyped in 100 healthy blood donors. Construct associated changes in XYLT1 promoter activity were detected for several sequence variants, whereas serum XT activity was only marginally affected.

Conclusions

Our findings describe for the first time the entire XYLT1 promoter sequence and provide new insights into transcriptional regulation of XT-I. Future studies should analyze the impact of regulatory XYLT1 promoter variations on XT-associated diseases.

【 授权许可】

   
2014 Faust et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Götting C, Kuhn J, Zahn R, Brinkmann T, Kleesiek K: Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II. J Mol Biol 2000, 304(4):517-528.
• [2]Cuellar K, Chuong H, Hubbell SM, Hinsdale ME: Biosynthesis of chondroitin and heparan sulfate in chinese hamster ovary cells depends on xylosyltransferase II. J Biol Chem 2007, 282(8):5195-5200.
• [3]Kjellen L, Lindahl U: Proteoglycans: structures and interactions. Annu Rev Biochem 1991, 60:443-475.
• [4]Heinegard D: Proteoglycans and more–from molecules to biology. Int J Exp Pathol 2009, 90(6):575-586.
• [5]Asano Y: Future treatments in systemic sclerosis. J Dermatol 2010, 37(1):54-70.
• [6]Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, De Wever O, Mareel M, Gabbiani G: Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180(4):1340-1355.
• [7]Kuhn J, Gressner OA, Götting C, Gressner AM, Kleesiek K: Increased serum xylosyltransferase activity in patients with liver fibrosis. Clin Chim Acta 2009, 409(1–2):123-126.
• [8]Götting C, Sollberg S, Kuhn J, Weilke C, Huerkamp C, Brinkmann T, Krieg T, Kleesiek K: Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis. J Invest Dermatol 1999, 112(6):919-924.
• [9]Prante C, Milting H, Kassner A, Farr M, Ambrosius M, Schön S, Seidler DG, Banayosy AE, Körfer R, Kuhn J, Kleesiek K, Götting C: Transforming growth factor beta1-regulated xylosyltransferase I activity in human cardiac fibroblasts and its impact for myocardial remodeling. J Biol Chem 2007, 282(36):26441-26449.
• [10]Faust I, Roch C, Kuhn J, Prante C, Knabbe C, Hendig D: Human xylosyltransferase-I - A new marker for myofibroblast differentiation in skin fibrosis. Biochem Biophys Res Commun 2013, 436(3):449-454.
• [11]Venkatesan N, Barre L, Bourhim M, Magdalou J, Mainard D, Netter P, Fournel-Gigleux S, Ouzzine M: Xylosyltransferase-I regulates glycosaminoglycan synthesis during the pathogenic process of human osteoarthritis. PLoS One 2012, 7(3):e34020.
• [12]Schreml J, Durmaz B, Cogulu O, Keupp K, Beleggia F, Pohl E, Milz E, Coker M, Ucar SK, Nürnberg G, Nürnberg P, Kuhn J, Ozkinay F: The missing “link”: an autosomal recessive short stature syndrome caused by a hypofunctional XYLT1 mutation. Hum Genet 2013, 133(1):29-39.
• [13]Bui C, Huber C, Tuysuz B, Alanay Y, Bole-Feysot C, Leroy JG, Mortier G, Nitschke P, Munnich A, Cormier-Daire V: XYLT1 Mutations in Desbuquois Dysplasia Type 2. Am J Hum Genet 2014, 94(3):405-414.
• [14]Pönighaus C, Ambrosius M, Casanova JC, Prante C, Kuhn J, Esko JD, Kleesiek K, Götting C: Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. J Biol Chem 2007, 282(8):5201-5206.
• [15]Roch C, Kuhn J, Kleesiek K, Götting C: Differences in gene expression of human xylosyltransferases and determination of acceptor specificities for various proteoglycans. Biochem Biophys Res Commun 2009, 391(1):685-691.
• [16]Müller B, Prante C, Kleesiek K, Götting C: Identification and characterization of the human xylosyltransferase I gene promoter region. J Biol Chem 2009, 284(45):30775-30782.
• [17]Müller B, Prante C, Knabbe C, Kleesiek K, Götting C: First identification and functional analysis of the human xylosyltransferase II promoter. Glycoconj J 2013, 30(3):237-245.
• [18]Frey UH, Bachmann HS, Peters J, Siffert W: PCR-amplification of GC-rich regions: ‘slowdown PCR’. Nat Protoc 2008, 3(8):1312-1317.
• [19]Bachmann HS, Siffert W, Frey UH: Successful amplification of extremely GC-rich promoter regions using a novel ‘slowdown PCR’ technique. Pharmacogenetics 2003, 13(12):759-766.
• [20]Geiser M, Cebe R, Drewello D, Schmitz R: Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. Biotechniques 2001, 31(1):88. -90, 92
• [21]Campbell P, Jacobsson I, Benzing-Purdie L, Roden L, Fessler JH: Silk-a new substrate for UDP-d-xylose:proteoglycan core protein beta-D-xylosyltransferase. Anal Biochem 1984, 137(2):505-516.
• [22]Weilke C, Brinkmann T, Kleesiek K: Determination of xylosyltransferase activity in serum with recombinant human bikunin as acceptor. Clin Chem 1997, 43(1):45-51.
• [23]Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
• [24]Schön S, Huep G, Prante C, Müller S, Christ R, Hagena FW, Kuhn J, Kleesiek K, Götting C: Mutational and functional analyses of xylosyltransferases and their implication in osteoarthritis. Osteoarthritis Cartilage 2006, 14(5):442-448.
• [25]Götting C, Kuhn J, Sollberg S, Huerkamp C, Brinkmann T, Krieg T, Kleesiek K: Elevated serum xylosyltransferase activity correlates with a high level of hyaluronate in patients with systemic sclerosis. Acta Derm Venereol 2000, 80(1):60-61.
• [26]Khair M, Bourhim M, Barre L, Li D, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M: Regulation of xylosyltransferase I gene expression by interleukin 1beta in human primary chondrocyte cells: mechanism and impact on proteoglycan synthesis. J Biol Chem 2013, 288(3):1774-1784.
• [27]Burge S, Parkinson GN, Hazel P, Todd AK, Neidle S: Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res 2006, 34(19):5402-5415.
• [28]Qin Y, Hurley LH: Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie 2008, 90(8):1149-1171.
• [29]Jung A, Ruckert S, Frank P, Brabletz T, Kirchner T: 7-Deaza-2′-deoxyguanosine allows PCR and sequencing reactions from CpG islands. Mol Pathol 2002, 55(1):55-57.
• [30]Britten RJ: Divergence between samples of chimpanzee and human DNA sequences is 5%, counting indels. Proc Natl Acad Sci U S A 2002, 99(21):13633-13635.
• [31]Hitraya EG, Varga J, Artlett CM, Jimenez SA: Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998, 41(11):2048-2058.
• [32]Holian J, Qi W, Kelly DJ, Zhang Y, Mreich E, Pollock CA, Chen XM: Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol 2008, 295(5):F1388-1396.
• [33]Chen SJ, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y, Varga J: The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281(30):21183-21197.
• [34]Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, Feghali-Bostwick C, Varga J: Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008, 173(4):1085-1099.
• [35]Schön S, Prante C, Müller S, Schöttler M, Tarnow L, Kuhn J, Kleesiek K, Götting C: Impact of polymorphisms in the genes encoding xylosyltransferase I and a homologue in type 1 diabetic patients with and without nephropathy. Kidney Int 2005, 68(4):1483-1490.
• [36]Schön S, Prante C, Bahr C, Tarnow L, Kuhn J, Kleesiek K, Götting C: The xylosyltransferase I gene polymorphism c.343G > T (p.A125S) is a risk factor for diabetic nephropathy in type 1 diabetes. Diabetes Care 2006, 29(10):2295-2299.
• [37]Verrecchia F, Mauviel A: Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002, 118(2):211-215.
• [38]Condac E, Dale GL, Bender-Neal D, Ferencz B, Towner R, Hinsdale ME: Xylosyltransferase II is a significant contributor of circulating xylosyltransferase levels and platelets constitute an important source of xylosyltransferase in serum. Glycobiology 2009, 19(8):829-833.
• [39]Wren JD, Forgacs E, Fondon JW 3rd, Pertsemlidis A, Cheng SY, Gallardo T, Williams RS, Shohet RV, Minna JD, Garner HR: Repeat polymorphisms within gene regions: phenotypic and evolutionary implications. Am J Hum Genet 2000, 67(2):345-356.
• [40]Akai J, Kimura A, Hata RI: Transcriptional regulation of the human type I collagen alpha2 (COL1A2) gene by the combination of two dinucleotide repeats. Gene 1999, 239(1):65-73.